H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. (2021)

R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)

Article  PubMed  Google Scholar 

J.M. Llovet, R.K. Kelley, A. Villanueva, A.G. Singal, E. Pikarsky, S. Roayaie et al., Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7(1), 6 (2021)

Article  PubMed  Google Scholar 

C. Estes, H. Razavi, R. Loomba, Z. Younossi, A.J. Sanyal, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 67(1), 123–133 (2018)

Article  CAS  PubMed  Google Scholar 

Z.M. Younossi, L. Henry, Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep. 3(4), 100305 (2021)

Article  PubMed  PubMed Central  Google Scholar 

E.E. Powell, V.W. Wong, M. Rinella, Non-alcoholic fatty liver disease. Lancet 397(10290), 2212–2224 (2021)

Article  CAS  PubMed  Google Scholar 

A. Villanueva, Hepatocellular Carcinoma. N Engl. J. Med. 380(15), 1450–1462 (2019)

Y. Li, Z.H. Gao, X.J. Qu, The adverse effects of sorafenib in patients with advanced cancers. Basic Clin. Pharmacol. Toxicol. 116(3), 216–221 (2015)

Article  CAS  PubMed  Google Scholar 

J. Krstic, I. Reinisch, K. Schindlmaier, M. Galhuber, Z. Riahi, N. Berger et al., Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Sci. Adv. 8(3), eabh2635 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

W.J. Turbitt, W. Demark-Wahnefried, C.M. Peterson, L.A. Norian, Targeting glucose metabolism to enhance immunotherapy: emerging evidence on intermittent fasting and calorie restriction mimetics. Front. Immunol. 10, 1402 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

I. Mohammed, M.D. Hollenberg, H. Ding, C.R. Triggle, A critical review of the evidence that metformin is a putative anti-aging drug that enhances Healthspan and extends Lifespan. Front. Endocrinol. (Lausanne). 12, 718942 (2021)

Article  PubMed  Google Scholar 

P. Andujar-Plata, X. Pi-Sunyer, B. Laferrere, Metformin effects revisited. Diabetes Res. Clin. Pract. 95(1), 1–9 (2012)

Article  CAS  PubMed  Google Scholar 

D.Q. Huang, H.B. El-Serag, R. Loomba, Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18(4), 223–238 (2021)

Article  PubMed  Google Scholar 

G. Nkontchou, E. Cosson, M. Aout, A. Mahmoudi, V. Bourcier, I. Charif et al., Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J. Clin. Endocrinol. Metab. 96(8), 2601–2608 (2011)

Article  CAS  PubMed  Google Scholar 

P.C. Tsai, H.T. Kuo, C.H. Hung, K.C. Tseng, H.C. Lai, C.Y. Peng et al., Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J. Hepatol. (2022)

V. Donadon, M. Balbi, M.D. Mas, P. Casarin, G. Zanette, Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 30(5), 750–758 (2010)

Article  CAS  PubMed  Google Scholar 

S. Singh, P.P. Singh, A.G. Singh, M.H. Murad, W. Sanchez, Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am. J. Gastroenterol. 108(6), 881–891 (2013). quiz 92

Article  CAS  PubMed  Google Scholar 

J. Li, P.Y. Hernanda, W.M. Bramer, M.P. Peppelenbosch, van J. Luijk, Q. Pan, Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS ONE. 10(6), e0127967 (2015)

Article  PubMed  PubMed Central  Google Scholar 

V. Cunha, H.P. Cotrim, R. Rocha, K. Carvalho, L. Lins-Kusterer, Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review. Ann. Hepatol. 19(3), 232–237 (2020)

Article  CAS  PubMed  Google Scholar 

G. Schimmack, R.A. Defronzo, N. Musi, AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes. Metab. 8(6), 591–602 (2006)

Article  CAS  PubMed  Google Scholar 

S. Siddharth, P. Kuppusamy, Q. Wu, A. Nagalingam, N.K. Saxena, D. Sharma, Metformin enhances the anti-cancer efficacy of Sorafenib via suppressing MAPK/ERK/Stat3 axis in hepatocellular carcinoma. Int. J. Mol. Sci. 23(15) (2022)

Y.G. Chung, E. Tak, S. Hwang, J.Y. Lee, J.Y. Kim, Y.Y. Kim et al., Synergistic effect of metformin on sorafenib in in vitro study using hepatocellular carcinoma cell lines. Ann. Hepatobiliary Pancreat. Surg. 22(3), 179–184 (2018)

Article  PubMed  PubMed Central  Google Scholar 

R. Harati, M. Vandamme, B. Blanchet, C. Bardin, F. Praz, R.A. Hamoudi et al., Drug-Drug interaction between metformin and sorafenib alters antitumor effect in hepatocellular carcinoma cells. Mol. Pharmacol. 100(1), 32–45 (2021)

Article  CAS  PubMed  Google Scholar 

A. Casadei Gardini, L. Faloppi, De S. Matteis, F.G. Foschi, N. Silvestris, F. Tovoli et al., Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale. Eur. J. Cancer. 86, 106–114 (2017)

Article  CAS  PubMed  Google Scholar 

Y.K. Chung, S. Hwang, G.W. Song, Y.J. Lee, K.H. Kim, C.S. Ahn et al., Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation. Ann. Hepatobiliary Pancreat. Surg. 22(4), 297–304 (2018)

Article  PubMed  PubMed Central  Google Scholar 

L. Schulte, B. Scheiner, T. Voigtlander, S. Koch, N. Schweitzer, S. Marhenke et al., Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver Int. 39(4), 714–726 (2019)

Article  CAS  PubMed  Google Scholar 

G. Orsi, A. Casadei-Gardini, Sorafenib and metformin: to be, or not to be, that is the question. Hepatobiliary Surg. Nutr. 8(4), 411–413 (2019)

Article  PubMed  PubMed Central  Google Scholar 

R. de Cabo, M.P. Mattson, Effects of intermittent fasting on health, aging, and disease. N Engl. J. Med. 381(26), 2541–2551 (2019)

Article  PubMed  Google Scholar 

C.L. Green, D.W. Lamming, L. Fontana, Molecular mechanisms of dietary restriction promoting health and longevity. Nat. Rev. Mol. Cell. Biol. 23(1), 56–73 (2022)

Article  CAS  PubMed  Google Scholar 

H.Y. Lai, H.H. Tsai, C.J. Yen, L.Y. Hung, C.C. Yang, C.H. Ho et al., Metformin resensitizes sorafenib-resistant HCC cells through AMPK-dependent autophagy activation. Front. Cell. Dev. Biol. 8, 596655 (2020)

Article  PubMed  Google Scholar 

M. Castejon, A. Plaza, J. Martinez-Romero, P.J. Fernandez-Marcos, R. Cabo, A. Diaz-Ruiz, Energy restriction and colorectal cancer: a call for additional research. Nutrients 12(1) (2020)

C. Lee, V.D. Longo, Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 30(30), 3305–3316 (2011)

Article  CAS  PubMed  Google Scholar 

L. Raffaghello, C. Lee, F.M. Safdie, M. Wei, F. Madia, G. Bianchi et al., Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. U S A 105(24), 8215–8220 (2008)

Article  CAS  PubMed  PubMed Central  Google Scholar 

de S. Groot, M.P. Vreeswijk, M.J. Welters, G. Gravesteijn, J.J. Boei, A. Jochems et al., The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 15, 652 (2015)

Article  PubMed  PubMed Central  Google Scholar 

J. Most, L.M. Redman, Impact of calorie restriction on energy metabolism in humans. Exp. Gerontol. 133, 110875 (2020)